StreetInsider.com News Articles

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Wed, 10 Jun 2026 07:00:00 -0400

BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel. Jeff Thramann, Executive Chairman, will be hosting the presentation and answering questions at the conclusion.

Recent

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Wed, 10 Jun 2026 07:00:00 -0400

BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel. Jeff Thramann, Executive Chairman, will be hosting the presentation and answering questions at the conclusion.

Recent

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Wed, 10 Jun 2026 07:00:00 -0400

BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel. Jeff Thramann, Executive Chairman, will be hosting the presentation and answering questions at the conclusion.

Recent

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Wed, 10 Jun 2026 07:00:00 -0400

BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel. Jeff Thramann, Executive Chairman, will be hosting the presentation and answering questions at the conclusion.

Recent

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Wed, 10 Jun 2026 07:00:00 -0400

BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel. Jeff Thramann, Executive Chairman, will be hosting the presentation and answering questions at the conclusion.

Recent

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Wed, 10 Jun 2026 07:00:00 -0400

BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel. Jeff Thramann, Executive Chairman, will be hosting the presentation and answering questions at the conclusion.

Recent

Aclarion partners with PRIA Healthcare for Nociscan reimbursement strategy

Tue, 09 Jun 2026 07:01:31 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced a partnership with PRIA Healthcare to establish a Market Access Program for its Nociscan platform, an AI-driven tool for chronic low back pain diagnosis.
The program aims to advance Nociscan through the reimbursement process to expand patient access and support commercial adoption. PRIA Healthcare will provide expertise in payer engagement, prior authorization support, and appeals management.
"Partnering with PRIA to establish this Market Access Program is a critical milestone as we execute our strategy to achieve payer coverage and expand market access for Nociscan," said Brent Ness, Chief Executive Officer of Aclarion.
Nociscan has received payer approval

Aclarion partners with PRIA Healthcare for Nociscan reimbursement strategy

Tue, 09 Jun 2026 07:01:31 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced a partnership with PRIA Healthcare to establish a Market Access Program for its Nociscan platform, an AI-driven tool for chronic low back pain diagnosis.
The program aims to advance Nociscan through the reimbursement process to expand patient access and support commercial adoption. PRIA Healthcare will provide expertise in payer engagement, prior authorization support, and appeals management.
"Partnering with PRIA to establish this Market Access Program is a critical milestone as we execute our strategy to achieve payer coverage and expand market access for Nociscan," said Brent Ness, Chief Executive Officer of Aclarion.
Nociscan has received payer approval

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Tue, 09 Jun 2026 07:00:00 -0400

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Tue, 09 Jun 2026 07:00:00 -0400

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Tue, 09 Jun 2026 07:00:00 -0400

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Tue, 09 Jun 2026 07:00:00 -0400

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Tue, 09 Jun 2026 07:00:00 -0400

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Tue, 09 Jun 2026 07:00:00 -0400

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Tue, 09 Jun 2026 07:00:00 -0400

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Tue, 09 Jun 2026 07:00:00 -0400

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Tue, 09 Jun 2026 07:00:00 -0400

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Tue, 09 Jun 2026 07:00:00 -0400

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access

Aclarion rejects Echo Lake Capital's $4 per share acquisition offer

Mon, 08 Jun 2026 07:05:59 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced that its board of directors unanimously rejected an unsolicited acquisition proposal from Echo Lake Capital and its principal, Ephraim Fields.
The healthcare technology company's board determined that Echo Lake's $4.00 per share offer significantly undervalues the company and does not reflect the range of opportunities available to create shareholder value. Aclarion develops biomarker and artificial intelligence technology to help physicians identify chronic low back pain locations.
According to the company's statement, the board concluded that the proposed transaction structure would disproportionately benefit Echo Lake at other shareholders' expense. The board said the offer would effectively use

Aclarion rejects Echo Lake Capital's $4 per share acquisition offer

Mon, 08 Jun 2026 07:05:59 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced that its board of directors unanimously rejected an unsolicited acquisition proposal from Echo Lake Capital and its principal, Ephraim Fields.
The healthcare technology company's board determined that Echo Lake's $4.00 per share offer significantly undervalues the company and does not reflect the range of opportunities available to create shareholder value. Aclarion develops biomarker and artificial intelligence technology to help physicians identify chronic low back pain locations.
According to the company's statement, the board concluded that the proposed transaction structure would disproportionately benefit Echo Lake at other shareholders' expense. The board said the offer would effectively use

Aclarion rejects Echo Lake Capital's $4 per share acquisition offer

Mon, 08 Jun 2026 07:05:59 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced that its board of directors unanimously rejected an unsolicited acquisition proposal from Echo Lake Capital and its principal, Ephraim Fields.
The healthcare technology company's board determined that Echo Lake's $4.00 per share offer significantly undervalues the company and does not reflect the range of opportunities available to create shareholder value. Aclarion develops biomarker and artificial intelligence technology to help physicians identify chronic low back pain locations.
According to the company's statement, the board concluded that the proposed transaction structure would disproportionately benefit Echo Lake at other shareholders' expense. The board said the offer would effectively use

Aclarion rejects Echo Lake Capital's $4 per share acquisition offer

Mon, 08 Jun 2026 07:05:59 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced that its board of directors unanimously rejected an unsolicited acquisition proposal from Echo Lake Capital and its principal, Ephraim Fields.
The healthcare technology company's board determined that Echo Lake's $4.00 per share offer significantly undervalues the company and does not reflect the range of opportunities available to create shareholder value. Aclarion develops biomarker and artificial intelligence technology to help physicians identify chronic low back pain locations.
According to the company's statement, the board concluded that the proposed transaction structure would disproportionately benefit Echo Lake at other shareholders' expense. The board said the offer would effectively use

Aclarion rejects Echo Lake Capital's $4 per share acquisition offer

Mon, 08 Jun 2026 07:05:59 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced that its board of directors unanimously rejected an unsolicited acquisition proposal from Echo Lake Capital and its principal, Ephraim Fields.
The healthcare technology company's board determined that Echo Lake's $4.00 per share offer significantly undervalues the company and does not reflect the range of opportunities available to create shareholder value. Aclarion develops biomarker and artificial intelligence technology to help physicians identify chronic low back pain locations.
According to the company's statement, the board concluded that the proposed transaction structure would disproportionately benefit Echo Lake at other shareholders' expense. The board said the offer would effectively use

Aclarion rejects Echo Lake Capital's $4 per share acquisition offer

Mon, 08 Jun 2026 07:05:59 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced that its board of directors unanimously rejected an unsolicited acquisition proposal from Echo Lake Capital and its principal, Ephraim Fields.
The healthcare technology company's board determined that Echo Lake's $4.00 per share offer significantly undervalues the company and does not reflect the range of opportunities available to create shareholder value. Aclarion develops biomarker and artificial intelligence technology to help physicians identify chronic low back pain locations.
According to the company's statement, the board concluded that the proposed transaction structure would disproportionately benefit Echo Lake at other shareholders' expense. The board said the offer would effectively use

Aclarion rejects Echo Lake Capital's $4 per share acquisition offer

Mon, 08 Jun 2026 07:05:59 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced that its board of directors unanimously rejected an unsolicited acquisition proposal from Echo Lake Capital and its principal, Ephraim Fields.
The healthcare technology company's board determined that Echo Lake's $4.00 per share offer significantly undervalues the company and does not reflect the range of opportunities available to create shareholder value. Aclarion develops biomarker and artificial intelligence technology to help physicians identify chronic low back pain locations.
According to the company's statement, the board concluded that the proposed transaction structure would disproportionately benefit Echo Lake at other shareholders' expense. The board said the offer would effectively use